Prognostic value of left ventricular ejection fraction combined with angiogenin-2 in chronic heart failure

Abstract:

Objective：To investigate the prognostic value of left ventricular ejection fraction（LVEF） combined with angiogenin-2（Ang2） in chronic heart failure（CHF）. Methods：LVEF and angiogenin-2 of 143 patients with chronic heart failure were measured from January 2010 to December 2012. The patients were followed up for one time every 3 months，and the follow-up period was 3 years. Cardiovascular death was considered as the end event. Logistic regression was used to analyze the risk factors for death in 3 years. ROC curve was used to analyze the effect of LVEF combined with Ang2 on the prognosis of patients with CHF. Results：The average of the patients was （69.56±6.14） years old. The male patient accounted for 66.43% of all patients（n=95） and 22.38%（n=32） patients died of cardiovascular events during follow-up. Multinomial logistic regression analysis showed that age（OR=0.92，95%CI=1.03~1.18，P=0.002），BMI（OR=1.53，95%CI=1.26~1.84，P=0.012），SBP（OR=1.06，95%CI=1.01~1.10，P=0.012），LVEF（OR=0.89，95%CI=0.81~0.94，P=0.001），Lg（BN）（OR=4.83，95%CI=1.75~12.78，P=0.001），Lg（Ang2）（OR=2.29，95%CI=1.03~5.53，P=0.008），Creatinine（OR=2.93，95%CI=1.44~6.12，P=0.012） are the independent risk factors for the prognosis of CHF. ROC analysis showed that LVEF combined with Ang2（auROC=0.847，95%CI=0.770~0.902） has better prognostic value than LVEF（auROC=0.778，95%CI=0.701~0.843） and Ang2（auROC=0.716，95%CI=0.634~0.788），P＜0.001. Conclusion：The combination of LVEF and Ang2 in the prognosis of patients with chronic heart failure seems to be a promising and useful clinical tool.